Skip to main content
. 2023 Apr 5;13(4):e067611. doi: 10.1136/bmjopen-2022-067611

Table 2.

Frequencies of individual constitutional and systemic symptoms in the overall PASC group and among the vaccinated and mAb-treated individuals

Total PASC
(n=5929)1
Vaccinated
PASC
(n=332)1
mAb treated
PASC
(n=444)1
Constitutional symptoms:
 Palpitation 591 (10.0) 25 (7.5) 50 (11.3)
 Headache 832 (14.0) 30 (9.0) 52 (11.7)
 Malaise and/or fatigue 882 (14.9) 42 (12.7) 76 (17.1)
Systemic symptoms:
 Cough 474 (8.0) 21 (6.3) 41 (9.2)
 Shortness of breath 2578 (43.5) 160 (50.9) 185 (41.7)
 Taste and/or smell changes 74 (1.2) 3 (0.9) 9 (2.0)
 Sleep disorder 957 (16.1) 50 (15.1) 71 (16.0)
 Cognitive impairment 248 (4.2) 17 (5.1) 32 (7.2)
 Mood/anxiety disorders 1001 (16.9) 31 (9.3) 59 (13.3)

* n (%).

PASC, postacute sequelae of SARS-CoV-2 infection.